Breast Oncology Briefing

Weekly. Updated automatically every Monday morning.

Week of September 14 to September 21, 2026

FDA approves imlunestrant plus abemaciclib in ESR1-mutated MBC

The lead this week is FDA's September 18 approval of imlunestrant (Inluriyo) plus abemaciclib (Verzenio) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one line of endocrine therapy, with Guardant360 CDx again approved as the companion diagnostic. It is the second new oral SERD regimen cleared this month and the second approval for Inluriyo in under a year. No major breast conference sat inside this window; the next big data event is the ESMO Congress in Madrid, October 23 to 27 (late-breaking abstracts were due September 8), so expect a relatively quiet stretch before a heavy news cycle.

1. Practice-Relevant Clinical

Lead: Imlunestrant plus abemaciclib for ESR1-mutated disease after endocrine progression (EMBER-3)

Trial and population. EMBER-3 (NCT04975308) randomized 874 adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer, previously treated with an aromatase inhibitor alone or with a CDK4/6 inhibitor, 1:1:1 to imlunestrant, investigator's choice endocrine therapy (fulvestrant or exemestane), or imlunestrant plus abemaciclib. Randomization was stratified by prior CDK4/6 inhibitor use, visceral metastasis, and geography. Patients eligible for a PARP inhibitor were excluded, meaning BRCA carriers were largely absent from the trial. ESR1 status was determined from ctDNA using Guardant360 CDx and limited to specific ligand-binding-domain mutations.

Practice implication. This is a new all-oral option at the post-AI progression decision point in ESR1-mutated disease, where fulvestrant and elacestrant currently sit, and the incremental value over endocrine monotherapy is the CDK4/6 inhibitor component. Monitoring is the familiar abemaciclib program (CBCs at baseline, every 2 weeks for the first 2 months, then monthly for the next 2 months); Lilly emphasizes no new monitoring requirements. Counseling points are diarrhea (86% any grade, 9% grade 3/4) and the food restriction for imlunestrant.

Skeptical read. The labeled population rests on an exploratory subgroup, the comparator was imlunestrant alone rather than fulvestrant, elacestrant, or an ADC, and OS is immature. Lilly's framing that "all available evidence suggests" switching at clinical progression outperforms earlier switching is company positioning against camizestrant's pre-progression strategy, not comparative trial evidence; no head-to-head data exist between the two approaches. Treat both labels as parallel options, not a settled hierarchy. Sources: FDA approval notice, Lilly press release, The ASCO Post.

Trastuzumab botidotin versus T-DM1 in HER2-positive MBC: phase 3 KL166-III-06 published in JCO

Design and population. Randomized, open-label, multicenter phase 3 in Chinese centers; 365 patients with HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab and a taxane, randomized 1:1 to trastuzumab botidotin monotherapy versus T-DM1. Primary endpoint was PFS by blinded independent central review. The prespecified final PFS analysis was published online in JCO on September 11, 2026 (doi:10.1200/JCO-26-00602), with the company announcement on September 14; the data were previously presented as a late-breaker at ESMO 2025.

Findings at median follow-up 14.9 months:

Practice implication. Nothing changes for US prescribing today: botidotin is not FDA-approved and T-DM1 is no longer the relevant comparator in this line in US practice, since T-DXd has displaced it after trastuzumab and taxane exposure. The useful read is that a next-generation HER2 ADC can produce deep, durable responses in post-trastuzumab/taxane disease, reinforcing how competitive the post-T-DXd HER2 landscape is likely to become. Source: CancerNetwork summary of the JCO publication and the Kelun-Biotech announcement.

2. FDA Landscape

Inluriyo combination approval: character of the decision

The September 18 action is described by Lilly as a full approval (not accelerated) of imlunestrant plus abemaciclib for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. It is the second approval for Inluriyo in under a year, following the September 2025 monotherapy approval. Guardant360 CDx was simultaneously approved as the companion diagnostic for this regimen, the same assay already tied to camizestrant, so both of this month's new oral SERD labels now run through one ctDNA platform. Two notes for the file: FDA's summary itself states the benefit was confined to the ESR1-mutated population on the basis of an exploratory subgroup analysis with immature OS, and the approval notice does not describe an advisory-committee review for this application. Sources: FDA, Lilly.

Correction worth restating: the camizestrant reversal

Readers tracking advisory committees should treat their prior expectations as corrected. On September 4 (just outside this window), FDA granted accelerated approval to camizestrant (Etcamah) with a CDK4/6 inhibitor upon detection of an emergent ESR1 mutation during first-line AI plus CDK4/6 inhibitor therapy, based on SERENA-6: 315 patients; median PFS 16 months (95% CI 12.7 to 18.2) versus 9.2 months (95% CI 7.2 to 9.5); HR 0.44 (95% CI 0.31 to 0.60); p<0.00001; OS not mature. That outcome reversed ODAC's April 30, 2026 vote of 6 to 3 against the application, after which FDA had extended the PDUFA date by three months to review supplemental analyses. A CRL would have been the expected result following that vote; the approval instead arrived, and FDA's cancer leadership called it the first approval of a therapy guided by detecting a resistance mutation in ctDNA before radiographic progression. With the imlunestrant combination now approved on the opposite trigger, switching at clinical progression, the agency has effectively endorsed both philosophies within two weeks. Sources: FDA accelerated approval notice, Targeted Oncology ODAC coverage, pharmaphorum.

Japan: first-line T-DXd plus pertuzumab and datopotamab deruxtecan approvals (September 16)

Japan's MHLW approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive unresectable or recurrent breast cancer, supported by DESTINY-Breast09 (1,157 patients randomized 1:1:1 to T-DXd plus pertuzumab, T-DXd monotherapy, or taxane plus trastuzumab plus pertuzumab; the monotherapy arm remains blinded). In the comparison reported to date versus taxane, trastuzumab, and pertuzumab: HR 0.56 (95% CI 0.44 to 0.71), p<0.00001; median PFS 40.7 months (95% CI 36.5 to not estimable) versus 26.9 months (95% CI 21.8 to not estimable); confirmed ORR 85.1% versus 78.6%; median duration of response 39.2 versus 26.4 months. MHLW also approved datopotamab deruxtecan first-line for HR-negative, HER2-negative unresectable or recurrent breast cancer in patients not candidates for PD-1/PD-L1 inhibitor therapy, supported by TROPION-Breast02 (644 patients versus investigator's choice chemotherapy): median OS 23.7 versus 18.7 months (HR 0.79, 95% CI 0.64 to 0.98, p=0.029) and median PFS 10.8 versus 5.6 months (HR 0.57, p<0.0001). Per Daiichi Sankyo's notice as reported by trade press, ILD occurred in 33.3% of Japanese patients on the T-DXd plus pertuzumab arm in DESTINY-Breast09, a number worth watching as this regimen moves toward potential US first-line use. These are Japan licenses; my searches found no corresponding US FDA action in this window, and I could not verify any pending US PDUFA date for either indication. Source: OncoDaily summary of the Daiichi Sankyo announcement.

No other FDA actions in breast oncology surfaced for this window in my searches: no complete response letters, no ODAC meetings, and no announced PDUFA date changes.

3. Survivorship / Supportive Care

This section is essentially empty this week. I found no survivorship, supportive care, symptom management, or long-term toxicity publication dated inside the window that met the bar for inclusion, and I would rather say so than pad the section. The nearest items fell just outside it, including a qualitative study of expressive writing in rural breast cancer survivors (Supportive Care in Cancer, published September 12) and a randomized mHealth supportive care trial in post-treatment survivors (Journal of Cancer Survivorship, published February 2026).

One genuinely relevant supportive-care tension did surface through this week's regulatory news, though it is an implication rather than new data: the two new SERD labels embed different testing burdens on patients without radiographic progression. Lilly's release argues that serial pre-progression ctDNA testing drives "patient anxiety from unnecessary testing" and avoidable cost, while the camizestrant pathway is only accessible to practices doing serial molecular monitoring. For survivorship-adjacent counseling, the trade-off between earlier detection of endocrine resistance and the anxiety, cost, and two-tier access created by surveillance testing is now a live clinical conversation rather than a theoretical one.

4. Translational / Horizon

Guardrail: nothing in this section is practice-changing today. These are signals about where the field is heading.

The ctDNA-guided switching question is now the field's central open experiment

With both September SERD approvals codified, the core translational question is whether intervening at detection of an emergent resistance mutation or MRD, before radiographic progression, improves long-term outcomes. FDA's own April 30 ODAC briefing framed exactly what remains unresolved: whether pre-radiographic switching improves long-term outcomes, the clinical meaningfulness of a PFS gain measured from mutation detection, whether PFS2 is adequate evidence of benefit, and immature, underpowered OS. The confirmatory obligations attached to camizestrant's accelerated approval are the structured test of that hypothesis. Source: FDA ODAC presentation, April 30, 2026.

Catch-up reading surfaced in this week's searches, dates unverified

Two ctDNA/MRD papers in npj Breast Cancer appeared in my searches, and I could not confirm their online publication dates fall within this window, so treat them as background rather than this week's news. First, long-term follow-up of the neoadjuvant ABCSG-34 trial: among 109 patients with ctDNA data and a median 7.1 years of follow-up, baseline ctDNA positivity was associated with inferior OS (HR 2.12, p=0.043), while ctDNA clearance trends did not reach significance, likely on sample size. Second, a prospective dual-analyte MRD study in 58 early-stage breast cancer patients tracking ctDNA and CTCs: MRD detection anticipated all relapses (100% sensitivity, median lead time 27.95 months), and a composite L-MRD score stratified 5-year recurrence risk at 2.2% versus 41.6% (HR 6.6, p=0.04; AUC 0.891; NPV 97.8%). Both are small, hypothesis-generating, and far from the interventional trials that would change monitoring practice. Sources: ABCSG-34 long-term ctDNA analysis and dual ctDNA/CTC MRD study.

Also on the horizon: ESMO Congress late-breaking abstracts were due September 8, so the next wave of breast translational and phase 3 news should land in Madrid, October 23 to 27.

Cuts Made (held back deliberately, ask if you want more on any of these):

Archive